Clinical Efficacy And SafetyPRT3789 was generally well tolerated with a low discontinuation rate, manageable adverse effects, and no severe adverse events reported.
Investment OpportunityPrelude shares represent a unique investment opportunity with significant potential upside.
Strategic PartnershipPrelude announced a collaboration with Pfizer Ignite enabling streamlined access to Pfizer’s significant resources, while retaining full ownership of all its programs.